Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470548 · ClinicalTrials.gov registry record · Phase 1
Abraxane and Alimta in Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT00470548 is a Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 49 participants.
The verdict
NCT00470548, a Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving paclitaxel albumin-stabilized nanoparticle formulation together with pemetrexed may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation when given together with pemetrexed and to see how well they work in treating patients with advanced non-small cell lung cancer, breast cancer, or other solid tumors.
Interventions
- DRUG Abraxane
- DRUG Alimta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2007-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470548
The ClinicalTrials.gov registry entry for NCT00470548 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abraxane is the first listed.
NCT00470548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470548 about?
NCT00470548 is a clinical study titled "Abraxane and Alimta in Advanced Solid Tumors". RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pemetrexed may stop the growth of tumor cells by blocking some of the enzyme...
What is the current status of trial NCT00470548?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2007-04. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00470548?
The interventions under investigation include: Abraxane (DRUG), Alimta (DRUG).
Who is sponsoring clinical trial NCT00470548?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.